IL1B and macrophage activation syndrome: Because active SD and disease flares are well‐known triggers of MAS episodes15, 17 and IL‐1 blockade has demonstrated high efficacy in inhibiting disease activity and improving SD outcome,8, 11, 12, 24 a reduction in MAS incidence might have been expected in our multicenter cohort with anakinra as first‐line treatment.